Physician profile
Sarah Abbott
NPI 1396402475
$13,203.01
in general payments reported to CMS, 2019-2025
7 companies · $5,665 in 2025
The $5,665 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $131 · 2023: $1,082 · 2024: $6,325 · 2025: $5,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Travel and Lodging: $1,938 · Food and Beverage: $1,093 · Education: $40.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,000.00 |
| Travel and Lodging | $1,938.34 |
| Food and Beverage | $1,093.08 |
| Education | $40.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,619.42 | 2022-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $242.29 | 2024-2025 | Invega Sustenna |
| Axsome Therapeutics, INC. | $220.69 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $61.84 | 2025 | Cobenfy |
| Alkermes, INC. | $25.75 | 2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $18.35 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $14.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.